To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions
NCT ID: NCT00883064
Last Updated: 2017-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2000-03-31
2000-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed
NCT00883506
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition
NCT01735344
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition
NCT01735318
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
NCT05061901
Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations
NCT03599466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
2
Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
18 Years
54 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Masson, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Anapharm
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.